TrialNet is testing rituximab-pvvr and abatacept, one after the other, to learn if using both treatments extend insulin production in people (ages 8-45) who were newly diagnosed with type 1 diabetes (T1D). Each therapy has a history of safety and effectiveness. Rituximab-pvvr is FDA-approved to...
For people age 12 – 35 years who have been diagnosed with type 1 diabetes in the past 3 months, this study tests two JAK inhibitors (abrocitinib and ritlecitinib) to see if either or both can preserve insulin production. TrialNet researchers are testing two different JAK...
The UW Medicine Diabetes Institute is the proud home of the COVERED Registry. COVERED stands for Community of Volunteers Engaged in Research to End Diabetes. The goal of this patient registry is to connect people interested in diabetes care with researchers studying diabetes and other...
[box class="summary"][/box]We are inviting you to participate in a research study to help us improve our understanding of diabetes and immune mediated diseases. The study consists of a computer registry where we store your contact, research, and health information, and a sample repository where we...
[box class="summary"][/box]TrialNet’s Pathway to Prevention studies the development of type 1 diabetes, and screens relatives of people with type 1 diabetes for their risk of developing the disease. Relatives of people with type 1 diabetes have about a 3 to 4 percent chance of being...
